Clinical trials: Graft-Versus-Host Disease
Acute Leukemia, Myelodysplastic Syndromes
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
The protocol is a phase I open label study evaluating the safety and feasibility of peri-transplant infusion of freshly expanded interferon gamma primed MSCs in adult and pediatric patients undergoing HCT for acute leukemia and…
- Trial name
- NCT04328714
- Testing
- Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Edwin Horwitz
Chronic Graft Versus Host Disease
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD…
- Trial name
- NCT05567406
- Testing
- Belumosudil
- Sponsor
- Kadmon, a Sanofi Company
Autoimmune Diseases, Inflammatory Disease
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
Interleukin 2 (IL-2) is a critical cytokine for the survival and function of regulatory T cells (LTreg). This cytokine has a dual role in the immune system.
- Conditions
- Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia, Systemic Lupus Erythematosus
- Trial name
- MuTreg (NCT05544448)
- Testing
- Blood sample taken at a single time point
- Where
- France
- Volunteers
- 67 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation
Primary Objective: It is hypothesized that the efficacy of Sitagliptin would reduce the incidence of grade II-IV acute Graft Versus Host Disease (GVHD) by day +100 post-transplant in patients undergoing alternative donor (related…
- Trial name
- SHIELD (NCT05149365)
- Testing
- Sitagliptin + Standard Prophylaxis, Standard Prophylaxis
- Where
- China
- Volunteers
- 190 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chronic Graft Versus Host Disease, Chronic GVHD
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
This research study is a Phase I clinical trial, which tests the safety of an investigational combination of IL-2 plus donor anti-inflammatory Treg cells and also tries to define the appropriate dose of the investigational…
- Conditions
- Chronic Graft Versus Host Disease, Chronic GVHD, Complications of Organ Transplant Stem Cells
- Trial name
- NCT01937468
- Testing
- Treg-enriched infusion, Interleukin-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Graft Vs Host Disease
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the…
- Trial name
- NCT05621759
- Testing
- Cyclophosphamide, Abatacept, Tacrolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NYU Langone Health
Hematologic Diseases, Acute Leukemia in Remission
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of…
- Conditions
- Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase
- Trial name
- NCT03842696
- Testing
- Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine)
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan Rogel Cancer Center
Graft Versus Host Disease, Hematologic Malignancy
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH). Recently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA…
- Trial name
- CY-MET-RIC (NCT06252870)
- Testing
- Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine
- Where
- 3 sites in France
- Volunteers
- 82 people
- Sponsor
- Nantes University Hospital
Fatigue, Graft Vs Host Disease
Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain.
Patients undergoing allogenic stem cell transplantation are regularly followed up in the outpatient clinic at Karolinska University Hospital.
- Conditions
- Fatigue, Graft Vs Host Disease, Cognitive Dysfunction
- Trial name
- NCT07365696
- Testing
- PET investigation
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Chronic Graft Versus Host Disease
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
This is an open-label phase I study of fostamatinib in combination with ruxolitinib for the treatment of chronic GvHD with a suboptimal response to corticosteroids.
- Trial name
- NCT06233110
- Testing
- Fostamatinib, Ruxolitinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stefanie Sarantopoulos, MD, PhD.
Ocular Graft-versus-host Disease
RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
rhPRG4-GVHD-001 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with moderate to severe dry eye secondary to chronic GVHD.
- Trial name
- NCT06495307
- Testing
- rhPRG4
- Where
- 2 sites in Australia
- Volunteers
- 3 people
- Sponsor
- Lubris Bio Pty Ltd
Stem Cell Transplant Complications, Graft Vs Host Disease
Multidisciplinary Intervention In Chronic GVHD
This research is being done to evaluate the feasibility and efficacy of a multidisciplinary, patient-centered intervention, Horizons Program, versus minimally enhanced standard care to improve quality of life, symptom burden and…
- Conditions
- Stem Cell Transplant Complications, Graft Vs Host Disease, Coping Skills, Quality of Life
- Trial name
- NCT04479995
- Testing
- Horizon Program, Usual Care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Graft-versus-host Disease
Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant
Recent published data suggest that specific alterations in intestinal metabolome signature of hematopoietic stem cell transplant (allo-SCT) recipients might influence incidence and severity of acute graft versus host disease…
- Trial name
- AlloBolome (NCT05186857)
- Where
- 9 sites in Spain
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Graft Versus Host Disease
Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT
Low-dose post-transplant cyclophosphamide have demonstrated therapeutic efficacy in allogeneic stem cell transplants which is comparable with the standard dose and also facilitates early hematological recovery.
- Trial name
- NCT07319000
- Testing
- Cyclophosphamide
- Where
- Mexico
- Volunteers
- 35 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Acute-graft-versus-host Disease
UCMSCs as Front-line Approach of Treatment for Patients With aGVHD
Background: Graft-versus-host disease (GVHD) is a devastating complication following allogeneic hematopoietic stem cell transplantation (HSCT) mediated by stimulation of antigen presenting cells (APCs) which leads to donor…
- Trial name
- GVHD Cyto-MSC (NCT03847844)
- Testing
- Umbilical cord derived mesenchymal stem cell
- Where
- Malaysia
- Volunteers
- 26 people
- Sponsor
- Cytopeutics Sdn. Bhd.
GVHD, Chronic, GVHD - Graft-Versus-Host Disease
Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).
This prospective observational study evaluates the association between psychiatric status, GvHD-related symptom severity, and health-related quality of life in patients with graft-versus-host disease.
- Conditions
- GVHD, Chronic, GVHD - Graft-Versus-Host Disease, GVHD, Quality of Life
- Trial name
- Psych-GvHD (NCT07314892)
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Medical University of Gdansk
Graft Versus Host Disease
Relationship Between "FODMAPs" and "GVHD"
With the stem cell transplanting increasing, patients which effected with "GVHD" were also increased. To evaluation the relationship between "FODMAPs" and "GVHD", Bone marrow transplant patients were recruited.
- Trial name
- NCT04660487
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Graft-versus-host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation…
- Trial name
- NCT06294678
- Testing
- Time of stem cell infusion
- Where
- 6 sites in China
- Volunteers
- 198 people
- Sponsor
- Anhui Provincial Hospital
Chronic Graft-Versus-Host Disease
A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease…
- Trial name
- NCT07138196
- Testing
- Adrixetinib
- Where
- 8 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Qurient Co., Ltd.
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)